NextCure Inc
For the period ended Dec 31, 2023. Filed Mar 21, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 21, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| | NEXTCURE, INC. | |
|---|---|---|
| | | |
| Date: March 21, 2024 | By: | /s/ Michael Richman |
| | Name: | Michael Richman |
| | | President and Chief Executive Officer |
Each person whose signature appears below constitutes and appoints Michael Richman and Steven P. Cobourn and each of them, jointly and severally, his or her attorneys-in-fact, each with full power of substitution, for him or her in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission.
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Signature | | Title | | Date |
|---|---|---|---|---|
| | | | | |
| /s/ Michael Richman | | President, Chief Executive Officer and Director | | March 21, 2024 |
| Michael Richman | | (Principal Executive Officer) | | |
| | | | | |
| /s/ Steven P. Cobourn | | Chief Financial Officer | | March 21, 2024 |
| Steven P. Cobourn | | (Principal Financial and Accounting Officer) | | |
| | | | | |
| /s/ David Kabakoff | | Chair of the Board | | March 21, 2024 |
| David Kabakoff, Ph.D. | | | | |
| | | | | |
| /s/ Anne Borgman | | Director | | March 21, 2024 |
| Anne Borgman, M.D. | | | | |
| | | | | |
| /s/ Ellen G. Feigal | | Director | | March 21, 2024 |
| Ellen G. Feigal, M.D. | | | | |
| | | | | |
| /s/ John G. Houston | | Director | | March 21, 2024 |
| John G. Houston, Ph.D. | | | | |
| | | | | |
| /s/ Elaine V. Jones | | Director | | March 21, 2024 |
| Elaine V. Jones, Ph.D. | | | | |
| | | | | |
| /s/ Chau Q. Khuong | | Director | | March 21, 2024 |
| Chau Q. Khuong | | | | |
| | | | | |
| /s/ Stephen Webster | | Director | | March 21, 2024 |
| Stephen Webster | | | | |
| | | | | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.